

InvitroCue Limited

ASX: IVQ

Transforming Bio-Analytics

**Corporate Structure:**

Shares on issue: 444M  
Market Cap: \$44.4 M

**Directors:**

**Dr Steven Fang**  
Founder & Executive Director

**Ms Jamie Khoo**  
Non-Executive Chairman

**Mr Chow-Yee Koh**  
Executive Director & Company Secretary

**Registered Office:**  
Level 2, 350 Kent St.  
Sydney NSW 2000 Australia

**Singapore Office:**  
11 Bioplis Way  
Helios 12-07/08  
Singapore 138667

**Email:**  
contact@invitrocue.com

**Website:**  
www.invitrocue.com

## InvitroCue signs Agreement with London School of Hygiene & Tropical Medicine

- Collaboration with world-leading institute in development of new drugs
- Agreement surrounding use of 3D *in vitro* technologies to establish leishmania spp. infection *in vitro* models
- *In vitro* technology to aid in creating novel models of predictive drug efficacy to support development of new drugs for treatment of leishmaniasis

**9 March 2016, London & Sydney:** The Directors of InvitroCue Limited (ASX:IVQ) (“InvitroCue” or “the Company”) are pleased to announce their recently signed Agreement to collaborate with the highly regarded London School of Hygiene & Tropical Medicine.

Under the Agreement, the organisations have begun a collaboration using 3D *in vitro* technologies to establish leishmania spp. infection *in vitro* models. These technologies, when integrated, could potentially offer a novel model for the *in vitro* screening of experimental drug compounds for anti-Leishmanial activity.

Leishmaniasis is a disease caused by leishmania, a parasite that is transmitted to humans through sand fly bites. Leishmaniasis affects people living in Asia, Africa, America and Europe manifesting as visceral (300,000 cases annually and 20,000 deaths), cutaneous (one million cases reported in the last five years) or mucocutaneous leishmaniasis. Over 300 million people in developing countries are at risk of leishmaniasis.

The London School of Hygiene & Tropical Medicine is a world-leading institute in the development of new drugs to treat leishmaniasis and many other diseases.

InvitroCue Executive Director, Dr Steven Fang commented: “We are very pleased to be collaborating with a world class institute such as the London School of Hygiene & Tropical Medicine. We are especially excited in the potential they see in our technology for near term and future use.”

“The Agreement provides us with a sense of validation for our technology and I look forward to updating shareholders with progress on further agreements and collaborations such as this in the near future.”

— ENDS —

### About the London School of Hygiene & Tropical Medicine:

The London School of Hygiene & Tropical Medicine is a world-leading centre for research and postgraduate education in public and global health, with more than 4,000 students and 1,000 staff working in over 100 countries. The School is one of the highest-rated research institutions in the UK, and among the world's leading schools in public and global health. Our mission is to improve health and health equity in the UK and worldwide; working in partnership to achieve excellence in public and global health research, education and translation of knowledge into policy and practice.

[www.lshtm.ac.uk](http://www.lshtm.ac.uk)

**For further information, please contact:**

Dr Steven Fang

Executive Director

Steven.fang@invitrocue.com

**Released through:**

Adam Jarvis, Six Degrees Investor Relations: +61 424 297 736 or adam.jarvis@sdir.com.au